{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:03Z","timestamp":1787020263047,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Luohu District Soft Science Research Program","award":["LX202402017"],"award-info":[{"award-number":["LX202402017"]}]},{"name":"Luohu District Soft Science Research Program","award":["LX202402017"],"award-info":[{"award-number":["LX202402017"]}]},{"name":"Luohu District Soft Science Research Program","award":["LX202402017"],"award-info":[{"award-number":["LX202402017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04297-6","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:00:56Z","timestamp":1749459656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Disproportionality analyses of Tapinarof-related adverse events based on the FAERS database"],"prefix":"10.1007","volume":"317","author":[{"given":"Xia","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"issue":"6","key":"4297_CR1","first-page":"707","volume":"35","author":"Psoriasis Research Group of Chinese Society Dermatology","year":"2021","unstructured":"Psoriasis Research Group of Chinese Society Dermatology (2021) Consensus on the treatment of psoriasis with benvitimod cream. Chin J Dermatovenereol 35(6):707\u2013711","journal-title":"Chin J Dermatovenereol"},{"issue":"1","key":"4297_CR2","first-page":"14","volume":"42","author":"J Yan","year":"2023","unstructured":"Yan J (2023) A new drug in treatment of psoriasis vulgaris: benvitimod. Chin J New Drugs Clin Rem 42(1):14\u201317","journal-title":"Chin J New Drugs Clin Rem"},{"issue":"24","key":"4297_CR3","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","volume":"385","author":"MG Lebwohl","year":"2021","unstructured":"Lebwohl MG, Stein GL, Strober B et al (2021) Phase 3 trials of Tapinarof cream for plaque psoriasis. N Engl J Med 385(24):2219\u20132229","journal-title":"N Engl J Med"},{"issue":"12","key":"4297_CR4","doi-asserted-by":"publisher","first-page":"e15931","DOI":"10.1111\/dth.15931","volume":"35","author":"S Nogueira","year":"2022","unstructured":"Nogueira S, Rodrigues MA, Vender R et al (2022) Tapinarof for the treatment of psoriasis. Dermatol Ther 35(12):e15931","journal-title":"Dermatol Ther"},{"issue":"16","key":"4297_CR5","first-page":"2401","volume":"40","author":"F Wang","year":"2024","unstructured":"Wang F, Zhang J, Zhuang W et al (2024) Real-world study evaluating novel Tetracycline adverse drug reactions based on the FAERS database. Chin J Clin Pharmacol 40(16):2401\u20132404","journal-title":"Chin J Clin Pharmacol"},{"key":"4297_CR6","doi-asserted-by":"publisher","first-page":"1417951","DOI":"10.3389\/fphar.2024.1417951","volume":"15","author":"X Guan","year":"2024","unstructured":"Guan X, Yang Y, Li X et al (2024) Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups. Front Pharmacol 15:1417951","journal-title":"Front Pharmacol"},{"issue":"9","key":"4297_CR7","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ijc.34848","volume":"154","author":"H Chen","year":"2024","unstructured":"Chen H, Yang G, Ma J (2024) Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database. Int J Cancer 154(9):1616\u20131625","journal-title":"Int J Cancer"},{"key":"4297_CR8","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, Cui Z, Lou S et al (2024) Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol 15:1338902 Published 2024 Feb 16","journal-title":"Front Pharmacol"},{"key":"4297_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","volume":"354","author":"R Lu","year":"2024","unstructured":"Lu R, Jiang Y, Du Z et al (2024) Multidimensional assessment of adverse events of bupropion: A large-scale data analysis from the FAERS database. J Affect Disord 354:649\u2013655","journal-title":"J Affect Disord"},{"key":"4297_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","volume":"347","author":"H Zhu","year":"2024","unstructured":"Zhu H, Qu Y, Du Z et al (2024) Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database. J Affect Disord 347:45\u201350","journal-title":"J Affect Disord"},{"issue":"4","key":"4297_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","volume":"84","author":"R Bissonnette","year":"2021","unstructured":"Bissonnette R, Stein Gold L, Rubenstein DS et al (2021) Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic Aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol 84(4):1059\u20131067","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"4297_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.5246\/jcps.2022.12.076","volume":"31","author":"J Hu","year":"2022","unstructured":"Hu J, Xue J, Shen J (2022) Research progress on the mechanism of Tapinarof in the treatment of atopic dermatitis and psoriasis. J Chin Pharm Sci 31(12):901\u2013911","journal-title":"J Chin Pharm Sci"},{"issue":"6","key":"4297_CR13","doi-asserted-by":"publisher","first-page":"e903","DOI":"10.1002\/iid3.903","volume":"11","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Pan Y, Zhang P et al (2023) AhR agonist Tapinarof ameliorates lupus autoimmunity by suppressing Tfh cell differentiation via regulation of the JAK2-STAT3 signaling pathway. Immun Inflamm Dis 11(6):e903","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"4297_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2023.12.013","volume":"154","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Boguniewicz M, Quintana FJ et al (2024) Tapinarof validates the Aryl hydrocarbon receptor as a therapeutic target: A clinical review. J Allergy Clin Immunol 154(1):1\u201310","journal-title":"J Allergy Clin Immunol"},{"issue":"21","key":"4297_CR15","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.3390\/ijms20215424","volume":"20","author":"M Furue","year":"2019","unstructured":"Furue M, Hashimoto-Hachiya A, Tsuji G (2019) Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci 20(21):5424","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4297_CR16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","volume":"87","author":"B Strober","year":"2022","unstructured":"Strober B, Stein Gold L, Bissonnette R et al (2022) One-year safety and efficacy of Tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol 87(4):800\u2013806","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4297_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00403-023-02749-5","volume":"316","author":"J Yan","year":"2023","unstructured":"Yan J, Chen S, Shi J (2023) 1% Tapinarof cream for the treatment of psoriasis: a network meta-analysis of randomized placebo- and calcipotriol-controlled trials. Arch Dermatol Res 316(1):31","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"4297_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jid.2023.07.027","volume":"144","author":"X Wang","year":"2024","unstructured":"Wang X, Mao D, Jia J et al (2024) Benvitimod inhibits IL-4- and IL-13-induced tight junction impairment by activating AHR\/ARNT pathway and inhibiting STAT6 phosphorylation in human keratinocytes. J Invest Dermatol 144(3):509\u2013519e7","journal-title":"J Invest Dermatol"},{"issue":"3","key":"4297_CR19","first-page":"363","volume":"33","author":"YY Ren","year":"2019","unstructured":"Ren YY, Yan H, Liang CP et al (2019) A case of eosinophilic pustular folliculitis. Chin J Dermatovenereol 33(3):363\u2013364","journal-title":"Chin J Dermatovenereol"},{"issue":"3","key":"4297_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jdcr.2019.01.002","volume":"5","author":"Y Kinoshita","year":"2019","unstructured":"Kinoshita Y, Kono T, Ansai SI et al (2019) An aggressive case of granulomatous eosinophilic pustular folliculitis on the face. JAAD Case Rep 5(3):237\u2013239 Published 2019 Feb 22","journal-title":"JAAD Case Rep"},{"issue":"3","key":"4297_CR21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaad.2020.04.181","volume":"84","author":"L Stein Gold","year":"2021","unstructured":"Stein Gold L, Bhatia N, Tallman AM, Rubenstein DS (2021) A phase 2b, randomized clinical trial of Tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes. J Am Acad Dermatol 84(3):624\u2013631. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.181","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"4297_CR22","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1111\/j.1468-3083.2011.04332.x","volume":"26","author":"R Bissonnette","year":"2012","unstructured":"Bissonnette R, Bolduc C, Maari C et al (2012) Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol 26(12):1516\u20131521. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04332.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4297_CR23","doi-asserted-by":"publisher","first-page":"204209862412792","DOI":"10.1177\/20420986241279213","volume":"15","author":"H Upadhyay","year":"2024","unstructured":"Upadhyay H, Aliberti S, Husband A, Chalmers JD, Hester K, De Soyza A (2024) Safety profile of drugs used in non-cystic fibrosis bronchiectasis: a narrative review. Ther Adv Drug Saf 15:20420986241279213 Published 2024 Sep 30. https:\/\/doi.org\/10.1177\/20420986241279213","journal-title":"Ther Adv Drug Saf"},{"key":"4297_CR24","doi-asserted-by":"crossref","unstructured":"Xiao H, Hooper PB, Umphress BA, Wolverton JE (2021) Keratoacanthoma centrifugum marginatum. Dermatol Online J.;27(3):13030\/qt5vp5f7bq. Published 2021 Mar 15","DOI":"10.5070\/D3273052774"},{"issue":"8","key":"4297_CR25","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3390\/molecules27082499","volume":"27","author":"P Kallimanis","year":"2022","unstructured":"Kallimanis P, Chinou I, Panagiotopoulou A et al (2022) Rosmarinus officinalis L. Leaf extracts and their metabolites inhibit the Aryl hydrocarbon receptor (AhR) activation in vitro and in human keratinocytes: potential impact on inflammatory skin diseases and skin Cancer. Molecules 27(8):2499. https:\/\/doi.org\/10.3390\/molecules27082499. Published 2022 Apr 13","journal-title":"Molecules"},{"key":"4297_CR26","doi-asserted-by":"publisher","unstructured":"Rebl H, Sawade M, Hein M et al (2022) Synergistic effect of plasma-activated medium and novel indirubin derivatives on human skin cancer cells by activation of the AhR pathway [published correction appears in Sci Rep.;12(1):4341. doi: 10.1038\/s41598-022-08218-9.]. Sci Rep. 2022;12(1):2528. Published 2022 Feb 15. https:\/\/doi.org\/10.1038\/s41598-022-06523-x","DOI":"10.1038\/s41598-022-06523-x"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04297-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:00:57Z","timestamp":1749459657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04297-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4297"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04297-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not needed for this study as all data were obtained from publicly accessible databases. Written consent from participants was not required, in accordance with national legislation and legal policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"802"}}